Related Experiment Video
Updated: Sep 21, 2025
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.6K
Molnupiravir in COVID-19: A Scoping Review
1Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India.
Current Drug Research Reviews
|May 31, 2022
Summary
Molnupiravir shows promise as an oral antiviral treatment for COVID-19. Further clinical studies are needed to confirm its effectiveness in preventing severe disease progression in outpatients.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- COVID-19 pandemic has led to extensive research into potential treatments.
- Repurposed drugs and novel antivirals are being investigated for efficacy against SARS-CoV-2.
- Molnupiravir has emerged as a promising orally available antiviral candidate for COVID-19.
Purpose of the Study:
- To conduct a scoping review on the use of molnupiravir against SARS-CoV-2 and COVID-19.
- To evaluate the therapeutic and prophylactic potential of molnupiravir.
- To assess the current evidence for molnupiravir's role in managing COVID-19.
Main Methods:
- Scoping review methodology employed.
- Analysis of preclinical studies in various animal models (ferrets, hamsters, mice).
- Evaluation of early and late-phase clinical trial data, including a Phase 3 global trial.
Main Results:
- Molnupiravir inhibits the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, demonstrating broad-spectrum antiviral activity.
- Preclinical studies showed encouraging therapeutic and prophylactic efficacy across multiple animal models.
- Early clinical studies and a large Phase 3 trial indicated significant benefits in symptomatic outpatients.
Conclusions:
- Molnupiravir presents potential as an oral therapy for COVID-19 treatment and prevention.
- Further clinical evaluation is essential to confirm its efficacy in outpatients and its ability to reduce disease progression.
- Molnupiravir warrants continued investigation as a valuable therapeutic option for COVID-19.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
16.0K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.0K
01:29Subviral Agents
142
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
142